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Abstract
IMPORTANCE Despite a global increase in sexually transmitted infections (STIs), there is limited
focus and investment in STI management within HIV programs, in which risks for STIs are likely to be
elevated.
OBJECTIVE To estimate the prevalence of STIs at initiation of HIV preexposure prophylaxis (PrEP;
emtricitabine and tenofovir disoproxil fumarate) and the incidence of STIs during PrEP use.
DATA SOURCES Nine databases were searched up to November 20, 2018, without language
restrictions. The implementers of PrEP were also approached for additional unpublished data.
STUDY SELECTION Studies reporting STI prevalence and/or incidence among PrEP users were
included.
DATA EXTRACTIONAND SYNTHESIS Data were extracted independently by at least 2 reviewers.
The methodological quality of studies was assessed using the Joanna Briggs Institute critical
assessment tool for prevalence and incidence studies. Random-effects meta-analysis was
performed.
MAINOUTCOMES ANDMEASURES Pooled STI prevalence (ie, within 3months of PrEP initiation)
and STI incidence (ie, during PrEP use, after 3 months).
RESULTS Of the 3325 articles identified, 88 were included (71 published and 17 unpublished). Data
came from 26 countries; 62 studies (70%) were from high-income countries, and 58 studies (66%)
were fromprograms only formenwho have sexwithmen. In studies reporting a composite outcome
of chlamydia, gonorrhea, and early syphilis, the pooled prevalence was 23.9% (95% CI,
18.6%-29.6%) before starting PrEP. The prevalence of the STI pathogen by anatomical site showed
that prevalence was highest in the anorectum (chlamydia, 8.5% [95% CI, 6.3%-11.0%]; gonorrhea,
9.3% [95% CI, 4.7%-15.2%]) compared with genital sites (chlamydia, 4.0% [95% CI, 2.0%-6.6%];
gonorrhea, 2.1% [95% CI, 0.9%-3.7%]) and oropharyngeal sites (chlamydia, 2.4% [95% CI,
0.9%-4.5%]; gonorrhea, 4.9% [95% CI, 1.9%-9.1%]). The pooled incidence of studies reporting the
composite outcome of chlamydia, gonorrhea, and early syphilis was 72.2 per 100 person-years (95%
CI, 60.5-86.2 per 100 person-years).
(continued)
Key Points
Question What is the burden of
sexually transmitted infections among
individuals using preexposure
prophylaxis (emtricitabine and tenofovir
disoproxil fumarate) for the prevention
of HIV infection?
Findings This systematic review and
meta-analysis identified 88 studies (71
published and 17 unpublished), with 26
(30%) from low- andmiddle-income
countries. For studies reporting a
composite outcome of chlamydia,
gonorrhea, and early syphilis, the pooled
prevalence was 23.9% at initiation of
HIV preexposure prophylaxis, and the
pooled incidence was 72.2 per 100
person-years during HIV preexposure
prophylaxis.
Meaning These estimates indicate a
high burden of sexually transmitted
infections among individuals initiating
preexposure prophylaxis and persistent
users of preexposure prophylaxis for
the prevention of HIV infection,
highlighting the opportunities for active
integration of services for sexually
transmitted infections and HIV
preexposure prophylaxis.
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE Given the high burden of STIs among individuals initiating PrEP
as well as persistent users of PrEP, this study highlights the need for active integration of HIV and STI
services for an at-risk and underserved population.
JAMA Network Open. 2019;2(12):e1917134. doi:10.1001/jamanetworkopen.2019.17134
Introduction
Preexposure prophylaxis (PrEP; emtricitabine and tenofovir disoproxil fumarate) for the prevention
of HIV infection is safe and effective when there is a high level of adherence.1-4 The World Health
Organization recommends the use of PrEP in subpopulations at substantial risk of HIV (ie, incidence
>3 per 100 person-years).5 Operationally, this means that PrEP services are prioritized for men who
have sex with men (MSM) in all world regions. Preexposure prophylaxis is also offered to the
HIV-negative partner in HIV-serodiscordant partnerships as a bridge to viral suppression in several
countries. In countries in East and Southern Africa with a high burden of HIV, PrEP services are
provided for sex workers or for young womenwhen the epidemiologic characteristics warrant.6
There is increasing interest and investment in implementing PrEP in low- andmiddle-income
countries (LMICs) by large donors, such as the US President’s Emergency Plan for AIDS Relief and the
Global Fund to Fight AIDS, Tuberculosis andMalaria. The Bill andMelinda Gates Foundation and
Unitaid have also made substantial investments in PrEP in LMICs. However, recent estimates of the
global burden of sexually transmitted infections (STIs)7 stress the need to consider programs that
could address the synergistic epidemic of HIV and STIs.
Global guidelines dictate that PrEP programs focus on people at substantial risk for HIV, who are
the same population at risk for other STIs. With growing interest in PrEP, moremembers of key
populations are motivated to engage with health care systems than ever before. This change
provides a unique opportunity to package PrEP services with more comprehensive sexual and
reproductive health services at a moment of peak receptivity, particularly in LMICs where such
services are currently limited. This plan is consistent with theWorld Health Organization Sustainable
Development Goals to end the HIV epidemic and other communicable diseases, to improve sexual
and reproductive health, and to achieve universal health coverage.8
In recent years, access to PrEP has shifted from provision in the context of demonstration
projects to wider implementation through national health systems.9 To synthesize the latest
available data to inform policies and practice around the provision of STI services within PrEP
programs, we conducted a systematic review to estimate the prevalence and incidence of STIs
among PrEP users. We supplemented data from the systematic reviewwith data from key PrEP
implementers who provided unpublished STI data. Previous systematic reviews have aimed to
compare STI rates among PrEP users and nonusers, focused only onMSM, used data almost
exclusively from high-income countries (HICs), and had limited search strategies.10-12 Since those
reviews, an expanding body of PrEP studies from LMICs provides additional data. Unlike previous
reviews, we aimed to describe the STI burden among PrEP users to highlight the potential lost
opportunities if STI services are not provided for individuals initiating PrEP as well as persistent PrEP
users. In particular, we contribute to the literature by providing pooled estimates according to
anatomical site (ie, pharyngeal, genital, or anal site) that are valuable for informing STI testing
recommendations and cost-effectiveness analyses.
Methods
This reviewwas conducted in 2 stages. First, a systematic review andmeta-analysis was conducted
in accordancewith the Preferred Reporting Items for Systematic Reviews andMeta-analyses (PRISMA)
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checklist13 (PROSPERO registration: CRD42018116721). Second, a contact list of 82 PrEP implementers
and/or researchers provided by the World Health Organization and some of us (J.J.O., J.D.T., F.T.-P.,
I.H.-M., and P.M.) was used. An email invitation to contribute unpublished STI data was sent to
individuals on the contact list with a follow-up email 1 week later if there was no response. No financial
incentives were offered for contributing the data.
We followed the guidelines in the Cochrane Handbook for Systematic Reviews of Interventions,
version 5.1.14 The following 9 databases were searched from inception to November 20, 2018,
without language restriction: Ovid MEDLINE (and In-Process and Other Nonindexed Citations and
Daily), Ovid Embase, Ovid Global Health, Ovid EconLit, EBSCO CINAHL Plus, EBSCO Africa-Wide
Information, Web of Science Core Collection, VHL LILACS, and Ovid Northern Light Life Sciences
Conference Abstracts. The 2 key concepts anchoring our search strategy were STIs and PrEP (full
details in eAppendix 1 in the Supplement). We included data from routine implementation programs
(PrEP, prospective cohorts, randomized clinical trials, or demonstration projects of oral PrEP) that
reported at least 1 of the following: frequency of STI testing and laboratory-confirmed STI positivity
(incidence or prevalence). We included data from key STIs: Chlamydia trachomatis; Neisseria
gonorrhoeae; Treponema pallidum; Trichomonas vaginalis;Mycoplasma genitalium; hepatitis A, B,
and C; and herpes simplex virus. We excluded systematic reviews, letters, editorials, studies using
only qualitative researchmethods, duplicated results from the same study, laboratory studies about
testing STI diagnostic performance, and studies restricting study populations by clinical outcomes
(eg, men with urethritis or women with cervicitis). Wemanually searched the references of existing
systematic reviews10-12 to ensure our search strategy included all relevant articles. Once duplicates
were removed, the titles and abstracts of articles were independently screened by at least 2
reviewers (M.K.S. and V.A.) according to a list of eligibility criteria; disagreements were discussed
with 1 of us (J.J.O.). Data were reviewed by 1 of us (J.J.O.) for consistency and accuracy. Variables used
for the data extraction are summarized in eAppendix 2 in the Supplement.We obtainedmissing data
from articles of interest by contacting the corresponding authors. We emailed PrEP implementers
to request data related to STI prevalence and/or incidence. Unpublished data were included if they
fulfilled the same inclusion criteria, and at the time of request, these data have not yet been
published or incorporated into existing publications.
Statistical Analysis
Baseline prevalence was defined as STI diagnoses within 3months of starting PrEP and confirmed by
laboratory test results. Incidence was defined as STI diagnoses while the individual was taking PrEP
and calculated as the number of new laboratory-confirmed STI cases divided by the total duration of
exposure to PrEP, calculated as cases per 100 person-years. We extracted reported incidence rates
and their 95%CIs when provided. If unavailable, we calculated the incidence by dividing the reported
numbers of STI cases and time at risk, and wemanually calculated the 95% CIs using the delta
method to derive log rates and SEs. When time at risk was not available, we contacted authors for
these data and excluded articles when we could not confidently measure STI prevalence or
incidence.
Random-effects meta-analysis was used to calculate across-study pooled estimates of STI
prevalence and STI incidence to account for sampling error and heterogeneity. Pooled estimates and
95% CIs were generated using a Freeman-Tukey–type double arcsine transformation to adjust for
variance instability.15 Statistical heterogeneity between studies was assessed with the I2 statistic.
Predefined subgroupmeta-analyses were based on the following covariates: anatomical site
(oropharyngeal, anorectal, or genital), study populations (MSM only or mixed [MSM and non-MSM]),
type of study (observational or experimental), and country income level (HIC or LMIC). Observational
studies include settings in which theremay be additional user costs for STI testing (but could also be
paid through a private insurance company, national health insurance, or from philanthropic groups)
and thusmay result in less systematic STI screening. Experimental studies follow a predefined study
protocol for STI testing and thus may have more systematic STI screening. High-income countrywas
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defined as any country with a gross national income per capita of US $12 056 or more in 2017.16
Random-effects metaregressionmodels were conducted to examine the association of these
variables with the effect size. Funnel plots were generated to assess for the possibility of small-study
effects that may be associated with publication bias. The Egger test was performed to confirm the
presence of this bias.17 All analyses were conducted using Stata, version 13.1 (StataCorp LLC). We
evaluated themethodological quality using the Joanna Briggs Institute critical assessment tool for
prevalence and incidence studies.18 A score of 5 (out of 10) or above was deemed to be of sufficient
quality to be included in the review.
Results
Of 3325 articles identified, 88 (71 published and 17 unpublished) met the inclusion criteria for
prevalence and incidence data (Figure 1). Table 1 summarizes the characteristics of these studies:
data came from 26 countries, mostly fromHICs (62 [70%]) and fromMSM-only programs (58
[66%]). Table 2 provides more data on included studies, all of which were deemed to be of sufficient
methodological quality as determined by the Joanna Briggs Institute tool (ie, score of5).2-4,18-86 A
summary of the countries that provided data is shown in Figure 2.
STI Prevalence and STI Incidence
Table 3 shows that, among studies reporting a composite outcome of any chlamydia, gonorrhea, and
early syphilis, the pooled prevalence was 23.9% (95% CI, 18.6%-29.6%). The prevalence of
chlamydia or gonorrhea by anatomical site was highest in the anorectum (chlamydia, 8.5% [95% CI,
6.3%-11.0%]; gonorrhea, 9.3% [95%CI, 4.7%-15.2%]) comparedwith genital sites (chlamydia, 4.0%
[95% CI, 2.0%-6.6%]; gonorrhea, 2.1% [95% CI, 0.9%-3.7%]) and oropharyngeal sites (chlamydia,
2.4% [95% CI, 0.9%-4.5%]; gonorrhea, 4.9% [95% CI, 1.9%-9.1%]). The forest plots for the pooled
prevalence by subgroups are provided in eAppendix 3 in the Supplement. For example, the
prevalence of chlamydia differed by study population (MSM, 6.9% [95% CI, 5.4%-8.6%]; mixed,
10.7% [95% CI, 0%-38.0%]), study type (observational, 7.9% [95% CI, 5.6%-10.4%]; experimental,
3.1% [95% CI, 1.1%-6.1%]), and country income level (HIC, 7.5% [95% CI, 5.7%-9.6%]; LMIC, 6.6%
[95% CI, 2.2%-12.8%]).
In studies that reported a composite outcome of any chlamydia, gonorrhea, and early syphilis,
the pooled incidence was 72.2 per 100 person-years (95% CI, 60.5-86.2 per 100 person-years). The
incidence of chlamydia or gonorrhea by anatomical site was highest in the anorectum (chlamydia,
Figure 1. PRISMA Flowchart
3325 Records identified through
database searching
1417 Duplicates removed
1908 Records remaining after 
removal of duplicates
1908 Titles or abstracts screened
258 Full-text articles assessed
for eligibility
1650 Records excluded for 
irrelevant content
88 Studies included in quantitative 
synthesis of incidence and 
prevalence
17 Extra sources of unpublished 
information added by PrEP 
implementers
187 Full-text articles excluded
109
55
23
No prevalence or incidence
Wrong study design
No PrEP users
PrEP indicates preexposure prophylaxis.
Table 1. Characteristics of Reviewed Studies
Reporting Sexually Transmitted Infection
Prevalence or Incidence
Characteristic
Studies, No. (%)
(N = 88)
Latest year of data
Before 2013 9 (10)
2013-2015 25 (28)
2016-2018 50 (57)
Not available 4 (5)
Population
MSM only 65 (74)
Mixed (ie, included
non-MSM)a
23 (26)
Type of study
Observational 73 (83)
Experimental 15 (17)
World Bank income level
High income 62 (70)
Low or middle income 26 (30)
Abbreviation: MSM, menwho have sex with men.
a Non-MSM included serodiscordant couples,
female sex workers, cisgender females,
transgender individuals, and heterosexual
individuals.
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Table 2. Descriptive Characteristics of Included Studies and the Risk-of-Bias Assessment Using the Joanna Briggs Institute Tool
Source Years of Data Study Type Country
Sample Size
of PrEP
Users, No.
MSM Only
or Mixed
Population, %a
Risk-of-Bias
Assessment
Abrams-Downey et al,19 2017 2013-2016 Observational United States 599 MSM, 93;
heterosexual, 7
8
Aloysius et al,20 2017 2016-2017 Observational United Kingdom 641 MSM 8
Anthony et al,21 2016 2015-2016 Observational United States 44 MSM, 89;
female, 5
8
Vuylsteke et al,22 2018 2015-2016 Observational Belgium 200 MSM 8
Baeten et al,23 2012 2008 Experimental Kenya
and Uganda
4758 MSM 7
Chaix et al,24 2018 2014 Experimental France
and Canada
400 MSM 8
Beymer et al,25 2018 2015-2016 Observational United States 275 MSM 8
Bhatia et al,26 2018 2012-2015 Observational United States 40 MSM 8
Blaylock et al,27 2018 2013-2016 Observational United States 159 MSM, 63;
female, 2;
serodiscordant, 22;
and young, 41
7
Bradshaw,28 2018 2017-2018 Observational United Kingdom 36 MSM 5
Bristow et al,29 2018 Not available Observational United States 394 MSM 9
Celum et al,30 2014 2008-2010 Experimental Kenya
and Uganda
1041 Serodiscordant, 100;
female, 20
7
Chau and Goings,31 2018 2017-2018 Observational United States 1423 MSM, 93;
female, 7
8
Cohen et al,32 2015 2012-2013 Observational United States 557 MSM 8
Cohen et al,33 2016 2012-2014 Observational United States 557 MSM 8
Coyer et al,34 2018 2015-2017 Observational The Netherlands 52 MSM 8
De Baetselier et al,35 2018 2015-2016 Observational Belgium 200 MSM 8
Delany-Moretlwe et al,36 2018 2016-2017 Observational South Africa
and Tanzania
431 Female
and young, 100
5
Elliott et al,37 2018 2016-2017 Observational United Kingdom 119 MSM 8
Freeborn et al,38 2018 Not available Observational United States 81 MSM 5
Golub et al,39 2018 Not available Observational United States 261 MSM 4
Grant et al,40 2014 2011-2013 Observational United States, Peru,
Brazil, Thailand,
South Africa,
and Ecuador
1225 MSM 8
Grinsztejn et al,41 2018 2014-2016 Observational Brazil 375 MSM 6
Wu et al,42 2018 2016-2017 Observational Taiwan 302 MSM, 92;
sex workers, 2;
female, 4;
heterosexual, 8
5
Hevey et al,43 2018 2010-2016 Observational United States 134 MSM, 96;
heterosexual, 4
5
Hojilla,44 2017 2014-2015 Observational United States 268 MSM 5
Hoornenborg et al,45 2018 2015 Observational The Netherlands 330 MSM 5
Hosek et al,46 2017 2013-2014 Observational United States 78 MSM 8
Hosek et al,47 2017 2013 Observational United States 200 MSM 9
Irungu et al,48 2016 2016 Observational Kenya
and Uganda
1694 Serodiscordant, 100 8
John et al,49 2018 2015-2016 Observational United States 104 MSM 8
Kenneth et al,50 2016 2005-2015 Observational United States 960 MSM, 76;
young, 12
6
Kipyego et al,51 2016 2008-2010 Observational Kenya 967 Serodiscordant, 100 8
Knapper et al,52 2018 2017 Observational Wales 96 MSM 8
Cotte et al,53 2018 2016-2017 Observational France
and Canada
162 MSM 7
(continued)
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Table 2. Descriptive Characteristics of Included Studies and the Risk-of-Bias Assessment Using the Joanna Briggs Institute Tool (continued)
Source Years of Data Study Type Country
Sample Size
of PrEP
Users, No.
MSM Only
or Mixed
Population, %a
Risk-of-Bias
Assessment
Lal et al,54 2017 2014-2015 Observational Australia 114 MSM, 95;
transgender, 1
8
Lalley-Chareczko et al,55 2018 2015 Observational United States 50 MSM 8
Liu et al,56 2016 2014-2015 Observational United States 437 MSM 8
La Fata et al,57 2017 2016 Observational France 202 MSM 6
Marcus et al,58 2013 2007-2009 Experimental Peru, Ecuador,
South Africa, Brazil,
Thailand, and
United States
2205 MSM 9
Marcus et al,59 2014 2007-2009 Experimental Peru, Ecuador,
South Africa, Brazil,
Thailand, and
United States
692 MSM 9
Marcus et al,60 2016 2012-2014 Observational United States 972 MSM 6
Mayer et al,61 2017 2005-2015 Observational United States 1631 MSM 8
McCormack and Dunn,62 2015 2012-2014 Experimental United Kingdom 545 MSM 9
McCormack et al,3 2016 2012-2015 Experimental United Kingdom 275 MSM 9
Molina et al,4 2015 2012-2015 Experimental France and Canada 199 MSM 8
Molina et al,63 2018 2015-2016 Experimental France 116 MSM 9
Molina et al,64 2017 2014-2016 Observational France and Canada 361 MSM 8
Nguyen et al,65 2018 2010-2015 Observational Canada 109 MSM 8
Nguyen et al,66 2016 2015-2016 Observational Canada 133 MSM 8
Noret et al,67 2018 2015-2018 Observational France 1049 MSM 8
Phanuphak et al,68 2018 2016-2017 Observational Thailand 1697 MSM 8
Hechter et al,69 2018 2014-2016 Observational United States 304 MSM 8
Reyniers et al,70 2018 2015-2016 Observational Belgium 200 MSM 9
Solomon et al,71 2014 2007-2011 Experimental Brazil, Peru,
Ecuador, United States,
South Africa, and
Thailand
1251 MSM 9
Tabidze et al,72 2018 2014-2016 Observational United States 2981 MSM 7
Tiberio et al,73 2016 2014-2015 Observational United States 33 MSM, 82;
young, 33;
and heterosexual, 15
7
Tiraboschi et al,74 2014 2013 Observational United Kingdom 393 MSM 7
Traeger et al,75 2018 2016-2018 Observational Australia 2490 MSM 9
Volk et al,76 2015 2012-2015 Observational United States 657 MSM 6
Zablotska et al,77 2015 2015 Observational Australia 268 MSM 6
Grant et al,2 2010 2007-2009 Experimental Peru, Ecuador,
South Africa, Brazil,
Thailand, and
United States
1251 MSM 9
Cotte et al,78 2018 2016-2017 Observational France 930 MSM 9
Hoornenborg et al,79 2018 2015-2016 Observational The Netherlands 376 MSM 7
Celum et al,80 2019 2016-2018 Observational South Africa and
Zimbabwe
412 Female
and young, 100
9
Hoornenborg et al,81 2018 2015-2016 Observational Amsterdam 376 MSM 9
Montaño et al,82 2019 2014-2017 Observational United States 183 MSM 7
Page et al,83 2018 2016-2017 Observational United States 170 MSM, 73;
female, 17;
and young, 19
7
Parsons et al,84 2018 Not available Observational United States 281 MSM 7
Antonucci et al,85 2014 2014 Experimental United Kingdom 511 MSM 7
Volk et al,86 2015 2011-2014 Observational United States 485 MSM 5
(continued)
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Table 2. Descriptive Characteristics of Included Studies and the Risk-of-Bias Assessment Using the Joanna Briggs Institute Tool (continued)
Source Years of Data Study Type Country
Sample Size
of PrEP
Users, No.
MSM Only
or Mixed
Population, %a
Risk-of-Bias
Assessment
Data direct from implementers
Kimberley Green, PhD
(written communication,
January 2019)
2018 Observational Vietnam 1221 Mixed NA
Nittaya Phanuphak, PhD
(written communication,
December 2018)
2016-2017 Observational Thailand 1697 Mixed NA
Jennifer Morton, MPH
(3P)
(written communication,
January 2019)
2017-2018 Observational South Africa 200 Female, 100 NA
Jennifer Morton, MHP
(POWER)
(written communication,
January 2019)
2017-2018 Observational South Africa
and Kenya
1255 Female, 100 NA
Pedro Carneiro, MPH
(written communication,
January 2019)
2015-2018 Observational United States 13 685 MSM NA
Andrew Grulich, PhD
(EPIC-NSW)
(written communication,
December 2018)
2016-2018 Observational Australia 8296 MSM NA
Michalina Montaño, PhD
(written communication,
January 2019)
2014-2017 Observational United States 365 MSM NA
Iskandar Azwa, MRCP
(written communication,
January 2019)
2018-2019 Observational Malaysia - MSM NA
Daisuke Mizushima, PhD
(written communication,
January 2019)
2018 Observational Japan 57 MSM NA
Amal Ben Moussa, MD,
and Mehdi Karkouri, MD
(written communication,
January 2019)
2018 Observational Morocco 189 MSM,
female sex workers
NA
Connie Celum, PhD
(Voice)
(written communication,
March 2019)
2008 Experimental South Africa,
Uganda,
and Zimbabwe
5029 Mixed NA
Connie Celum, PhD
(written communication,
March 2019)
2008 Experimental Kenya
and Uganda
4758 Heterosexual
and serodiscordant, 100
NA
Connie Celum, PhD
(Plus pills)
(written communication,
March 2019)
2016 Observational South Africa 150 Mixed NA
de Baetselier, PhD
(written communication,
March 2019)
2018 Observational Togo 103 MSM NA
de Baetselier, PhD
(written communication,
March 2019)
2018 Observational Cote D’Ivoire 100 MSM NA
de Baetselier, PhD
(written communication,
March 2019)
2018 Observational Burkina Faso 103 MSM NA
Ellen White, MSc
(PROUD)
(written communication,
February 2019)
2012-2016 Experimental United Kingdom 275 MSM NA
Abbreviations: 3P, PrEP-Power-Pride; EPIC-NSW, Expanded PrEP Implementation in
Communities–New SouthWales; MSM, menwho have sex with men; NA, not applicable;
Plus pills, Choices for Adolescent PreventionMethods for South Africa, Pilot Study B;
POWER, Prevention Options for Women Evaluation Research; PrEP, preexposure
prophylaxis; PROUD, Pre-exposure Option for Reducing HIV in the UK; Voice, Vagina and
Oral Interventions to Control the Epidemic.
a Mixed population may not add up to 100% as individuals may belong to more than 1
category or there are missing data. May include cisgender females, heterosexual
individuals, transgender individuals, serodiscordant couples, female sex workers, or
young people (<25 years of age).
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29.9 per 100 person-years [95% CI, 24.1-37.1 per 100 person-years]; gonorrhea, 21.6 per 100 person-
years [95% CI, 16.4-28.4 per 100 person-years]) compared with genital sites (chlamydia, 10.4 per
100 person-years [95% CI, 9.2-11.8 per 100 person-years]; gonorrhea, 9.9 per 100 person-years
[95% CI, 8.3-11.8 per 100 person-years]) and oropharyngeal sites (chlamydia, 4.6 per 100 person-
years [95% CI, 3.3-6.3 per 100 person-years]; gonorrhea, 19.7 per 100 person-years [95% CI, 16.0-
24.3 per 100 person-years]). Compared with oropharyngeal chlamydia, the reported incidence of
oropharyngeal gonorrhea was significantly higher. The forest plots for the pooled incidence by
subgroup are provided in eFigures 1 to 11 in the Supplement (eAppendix 3 in the Supplement). The
incidence of chlamydia differed by study type (observational, 22.4 per 100 person-years [95% CI,
18.6-27.0 per 100 person-years]; experimental, 17.0 per 100 person-years [95% CI, 8.7-33.3 per 100
person-years]) and country income level (HIC, 22.1 per 100 person-years [95% CI, 18.5-26.5 per 100
person-years]; LMIC, 8 per 100 person-years [95% CI, 5.6-11.5 per 100 person-years]).
A few observations from themetaregression results are notable (eTables 1-7 in the
Supplement). The prevalence of gonorrhea was higher in studies that enrolled MSM only (adjusted
odds ratio [AOR], 1.11 [95% CI, 1.00-1.22]) compared with studies also containing non-MSM
populations (eTable 2 in the Supplement). The incidence of chlamydia was higher in the anorectum
(AOR, 7.25 [95% CI, 4.83-10.86]) and genital sites (AOR, 2.20 [95% CI, 4.83-10.86]) than in
oropharyngeal sites, and it was higher in HICs (AOR, 4.92 [95% CI, 2.35-10.32]) than in LMICs
(eTable 5 in the Supplement). Visual inspection of the funnel plots and the Egger test found an
indication of small-study effects, with underestimation of the true chlamydia incidence rate
(eFigure 7 in the Supplement). The incidence of gonorrhea was lower in genital sites than in
oropharyngeal sites (AOR, 0.50 [95% CI, 0.32-0.77]), and it was higher in HICs than in LMICs (AOR,
7.03 [95% CI, 2.62-18.88]; eTable 6 in the Supplement). Visual inspection of the funnel plots and the
Egger test found an indication of small-study effects, with underestimation of the true gonorrhea
Figure 2. Countries That Provided Data for the Systematic Review
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incidence rate (eFigure 6 in the Supplement). The incidence of early syphilis was higher in HICs (AOR,
3.93 [95% CI, 1.36-11.41]) than in LMICs (eTable 7 in the Supplement). Visual inspection of the funnel
plots and the Egger test found an indication of small-study effects, with underestimation of the true
early hepatitis C incidence rate (eFigure 11 in the Supplement).
Discussion
This systematic review andmeta-analysis consolidates the published and unpublished evidence of
the high STI burden among individuals initiating PrEP as well as among persistent PrEP users. Our
findings underscore the lost opportunities if STI services are not provided for individuals initiating
PrEP and highlights the opportunity to harness the growing interest in providing PrEP programs
globally to be a gateway to providemore comprehensive sexual and reproductive health services for
PrEP users. There are opportunities for economies of scope and scale to control STIs by leveraging
the growing infrastructure of PrEP delivery and access to higher-risk individuals. Synergistically, the
identification of high-risk individuals with STIs can be a gateway for the provision of PrEP.
Implementing more frequent STI screening and testing and partner services among high-risk
individuals may potentially lessen the effect of STI epidemics.87,88 As we strengthen the delivery of
sexual and reproductive health services for PrEP users globally, there may also be a positive flow-on
effect for nonusers living with HIVwho also are at high risk for STIs, and other nonusersmay also be
able to access these services.
The high pooled prevalence of STIs among those starting PrEP reinforces the belief that we are
reaching groups at high risk for HIV and STIs, and the high pooled incidence emphasizes the need
for ongoing STI testing and treatment services because PrEP users remain at high risk for STIs. Our
study complements other meta-analyses of STI incidence amongMSM only10-12; however, we extend
their findings by examining sources of heterogeneity according to anatomical site of detection, study
population composition, country income level, and study type. We noted a high level of
heterogeneity in our pooled estimates, whichmay be due to additional factors, including differences
Table 3. Pooled Prevalence of STIsWhen Starting PrEP and Pooled Incidence of STIs, by Anatomical Site of Detection
Pathogen
Prevalence Incidence
No. of
Studies
Pooled
Total Sample
Size, No.
Prevalence
(95% CI) I2 Statistic, % P Value
No. of
Studies
Pooled
Total Sample
Size, No.
Incidence per 100
Person-Years
(95% CI) I2 Statistic, % P Value
Chlamydia trachomatis
Any site 12 4918 10.8 (6.4-16.1) 97 <.001 14 6756 21.5 (17.9-25.8) 97 <.001
Genital 6 1019 4.0 (2.0-6.6) 66 .01 9 1698 10.4 (9.2-11.8) 0 .78
Anorectal 8 1660 8.5 (6.3-11.0) 61 .01 11 2171 29.9 (24.1-37.1) 87 <.001
Oropharyngeal 5 939 2.4 (0.9-4.5) 63 .03 7 1237 4.6 (3.3-6.3) 46 .10
Neisseria gonorrhoeae
Any site 14 6340 11.6 (7.6-16.2) 96 <.001 13 6462 37.1 (18.3-25.5) 96 <.001
Genital 6 2166 2.1 (0.9-3.7) 70 .01 8 1564 9.9 (8.3-11.8) 28 .20
Anorectal 8 1558 9.3 (4.7-15.2) 92 <.001 11 2171 21.6 (16.4-28.4) 90 <.001
Oropharyngeal 5 940 4.9 (1.9-9.1) 83 <.001 8 1646 19.7 (16.0-24.3) 76 <.001
Treponema pallidum a 22 9757 5.0 (3.1-7.4) 95 <.001 23 12 459 11.6 (9.2-14.6) 92 <.001
Hepatitis A virus 1 1049 5.4 (4.1-7.0) NA NA NA NA NA NA NA
Hepatitis B virus 4 4370 1.3 (0.1-3.5) 95 <.001 2 1353 1.2 (0.6-2.6) 0 .53
Hepatitis C virus 4 2555 2.0 (0.8-3.7) 84 <.001 8 3786 0.3 (0.1-0.9) 87 <.001
Mycoplasma genitalium 1 198 17.2 (12.2-23.2) NA NA NA NA NA NA NA
Trichomonas vaginalis 2 1379 5.9 (4.7-7.2) NA NA 1 50 0 NA NA
Any C trachomatis,
N gonorrhoeae,
or T pallidum
16 8431 23.9 (18.6-29.6) 97 <.001 11 6301 72.2 (60.5-86.2) 95 <.001
Abbreviations: NA, not applicable; PrEP, preexposure prophylaxis; STI, sexually
transmitted infection.
a Early syphilis, primary or secondary syphilis, or early latent syphilis.
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in background HIV prevalence in country or setting, case mix of populations (ie, sampling different
underlying populations: different distributions of socioeconomic status, race/ethnicity, age, or sexual
mixing networks), study designs (variable inclusion criteria for PrEP, different frequency of testing),
and STI diagnostic protocols (eg, the Pre-exposure Prophylaxis Initiative [iPrEx] trial2,40 analyzed
urethral samples for chlamydia or gonorrhea only if leucocytes were present in urine, whereas
Australian demonstration projects75 did not impose such reliance on urine leucocytes). Nevertheless,
despite this high level of heterogeneity between studies, the consistently high STI prevalence and
incidence reported in individual studies cannot be ignored.
This systematic review uncovered several important gaps in evidence. First, we found only 1
article that reported antimicrobial-resistantM genitalium among PrEP users.35 With expected high
yields of positive samples fromPrEP users, PrEP programsmay be useful as sentinel surveillance sites
for STI–antimicrobial resistancemonitoring for N gonorrhoeae andMgenitalium. Second, there are
inconsistencies in how STI prevalence and STI incidence are reported, precluding their inclusion in
meta-analyses. For future meta-analyses, reporting the number of cases with person-years at risk or
incidence rateswith 95%CIswould be aminimum requirement.We recommend disaggregating STI
prevalence and STI incidence by pathogen and subpopulations (eg, age, sex, or transgender identity).
Policy Implications
Our study is useful to advocate for improved access to STI services for PrEP users and to inform
program design and cost-effectiveness analyses. There is a clear need to facilitate the development
of affordable, accurate, and easy-to-use point-of-care tests for STIs and developing models for STI
casemanagement in resource-constrained settings. A reevaluation is needed of how diagnostic costs
can be reduced and how economies of scope and scale may be gained from using the existing
infrastructure of cartridge-basedmolecular diagnostic machines that are used for other diseases
(such as tuberculosis). The current interest, demand, and support for PrEP services in LMICs is
predicated on a need to provide PrEP as simply and cheaply as possible. Therefore, a tension exists
between the increasing costs and complexity of PrEP implementation and the opportunity and need
to provide effective STI services. Amarket and technology landscape report for STI diagnostics
(similar to HIV self-testing89) would be a helpful resource for PrEP programs. Furthermore, guidance
from international authorities, such as theWorld Health Organization, will be needed to definewhat
may be considered as essential sexual health services compared with enhanced services, particularly
in resource-constrained settings.
There are ongoing challenges in implementing integrated STI services within PrEP programs.
The key challenges are related to STI diagnostics, program logistics of combined STI and PrEP
delivery, and lack of STI capacity building. Particularly for LMICs, there is a lack of access to triple–
anatomical site sampling (ie, testing from oropharyngeal, urogenital, and anorectal sites), which is
critical for detecting STIs in MSM.90 This situation is usually related to lack of funding, so
considerations should be given to the burgeoning evidence for pooled samples testing.91 A robust
economic case is pertinent because cost has been raised as a major barrier, even in HICs where direct
user costs may be incurred by those with no health insurance.
Strengths and Limitations
The strength of our review is the inclusion of data from 26 countries including non-MSM populations,
LMIC settings, and previously unreported STI data. Our findings should be considered in light of
several limitations. First, there is a potential for selection and detection bias. The high STI prevalence
for individuals starting PrEPmay reflect the inclusion criteria for some PrEP programs (ie, some
clinicians may encourage same-day referral for PrEP when a rectal STI is diagnosed). The pooled
incidencemay be overestimated owing tomore frequent testing and frommore anatomical sites.
Second, not all PrEP-related publications focused on reporting STI data. Wemitigated this factor by
approaching PrEP programs for unpublished STI data. Third, we included only laboratory-confirmed
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STIs. Therefore, most estimates came fromHICs where diagnostics were available, whereas
estimates obtained in LMICs are representative of externally funded research programs.
Conclusions
Given the high STI burden among individuals initiating PrEP and among persistent PrEP users, there
are opportunities to leverage the global interest in PrEP policy and the development of programs to
actively promote the integration of STI services, which includes appropriate asymptomatic testing,
treatment, and targeted vaccination. Currently, fewer STI data are available from programs offering
PrEP to women, young people, serodiscordant couples, and transgender individuals outside HICs.
More data would help guide recommendations on the frequency and optimal STI testing approaches
for all population groups accessing PrEP.
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